Webinar-on-demand: Ultra-High Throughput Hit Discovery Against Protein-Protein Interactions: A SARS-CoV-2 Showcase

Webinar: A SARS-CoV-2 Showcase

Within the European Lead Factory (ESCulab), we started a program to identify novel hits that inhibit the interaction between the viral spike protein subunit S1 and human angiotensin-converting enzyme 2 (hACE2). At Pivot Park Sreening Centre, we developed a primary HTRF assay followed by a very comprehensive triaging casacde of multiple selection assays. We found high-quality hits comprising of various compound clusters and singletons, whereof the most promising compounds were resynthesized and validated for activity.

  • Ultra-High Throughput Screening
  • Protein-Protein Interactions
  • Comprehensive hit triaging
  • Mass spectrometry uHTS assay
  • Hit validation and evaluation
  • Biophysical assays: TSA & ASMS


About the presenter:

Fleur Kleinpenning, PhDDr. Fleur Kleinpenning, Senior Scientist – Chemical Biology started as scientist at Pivot Park Screening Centre (PPSC) in Oss, the Netherlands in March 2020. After achieving her PhD in the field of chemical biology, she explored the field of mass spectrometry and proteomics during her postdoc. At PPSC, she is involved in numerous commercial, academic, and internal projects focusing on cellular and biochemical assay development, ultra high-throughput screening (uHTS), and matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF-MS) based uHTS.r

(Duration of this webinar is approximately 45 minutes)